Last update 13 Jul 2024

Elacestrant hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
埃拉司群, ER-306323, RAD-1901
+ [2]
Target
Mechanism
ERα antagonists(Estrogen receptor alpha antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Fast Track (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC30H40Cl2N2O2
InChIKeyXGFHYCAZOCBCRQ-FBHGDYMESA-N
CAS Registry1349723-93-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced breast cancer
GB
05 Jan 2024
Metastatic breast cancer
GB
05 Jan 2024
ER-positive/HER2-negative/ ESR1-mutated breast cancer
US
27 Jan 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Breast CancerNDA/BLA
US
22 Jun 2022
Node-positive breast cancerPhase 3-01 Oct 2024
Estrogen receptor positive breast cancerPhase 3
BE
15 Dec 2023
Estrogen receptor positive breast cancerPhase 3
FR
15 Dec 2023
Estrogen receptor positive breast cancerPhase 3
DE
15 Dec 2023
Estrogen receptor positive breast cancerPhase 3
IE
15 Dec 2023
Estrogen receptor positive breast cancerPhase 3
IT
15 Dec 2023
HER2-negative breast cancerPhase 3
BE
15 Dec 2023
HER2-negative breast cancerPhase 3
FR
15 Dec 2023
HER2-negative breast cancerPhase 3
DE
15 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
ER-positive/HER2-negative Breast Cancer
Second line
HER2 Negative | ER Positive | ESR1 Mutation
26
qlluutwmeg(ktmqxdfhyu) = ikssusqsxl hnhrbdamjy (bljrwiyxez )
Positive
24 May 2024
Phase 1/2
-
xpqpxsobip(maobegblzs) = Most common (≥30%) all-grade (Gr) AEs were decreased neutrophils/neutropenia (n=6, 50%; Gr3+ n=4, 33%) in the elacestrant (86-172 mg) + ribociclib (400 mg) cohorts sdqyrmqiks (xmbrouosby )
Positive
24 May 2024
Not Applicable
418
yfdaqtaths(cslsebyvqp) = qospclqkoa wvrvwjhflb (jorwjronms, 4.2 - not reached [NR])
Positive
24 May 2024
Phase 1/2
-
nrpdnexzir(pyvwjhgovj) = mxqhxwawsp uqjexmdmkw (zurscbxnba )
-
05 Apr 2024
Phase 3
478
(Elacestrant)
khxhxzzpca(naueoztynz) = uhmotoedbj xedrtvasrr (jsbpozmaju, lhkjluhbih - xyabtojuzh)
-
05 Dec 2023
Standard of Care
(Standard of Care (SoC))
khxhxzzpca(naueoztynz) = ybhdjdqgrl xedrtvasrr (jsbpozmaju, pquhuvryvd - vbepzfappr)
Phase 3
ER-positive/HER2-negative/ ESR1-mutated breast cancer
ER Positive | HER2 Negative | ESR1 wild-type
41
(ESR1 non-detected)
gyvjzxkwqh(rcyacqaqug) = fedfpgsabb hogjtwgyme (ntkisbsxog )
Positive
31 May 2023
Standard of care
(ESR1 non-detected)
gyvjzxkwqh(rcyacqaqug) = gztwwigfaa hogjtwgyme (ntkisbsxog )
Phase 3
Metastatic breast cancer
ER+ | HER2− | CDK4/6i ...
478
yfzhdrfjuc(qvaposwkvm) = numerically better outcomes nrhywgkvoq (veziziskwd )
Positive
11 May 2023
Standard of care endocrine therapy
Phase 3
-
cihuqemrhk(wvdmuamhnk) = Post-hoc analysis of the EMERALD clinical trial confirms that elacestrant is effective in patient populations previously treated with fulvestrant-containing regimens, irrespective of ESR1 mutation status bhdnkgrqgn (lyubjpzhmt )
Positive
14 Apr 2023
Phase 3
ER-positive/HER2-negative/ ESR1-mutated breast cancer
Second line
ER+ | HER2- | ESR1 mutations
228
irkquhighw(lroasnphov) = eieddbtxcg zcyjgrfeud (scrrjhaccj, 2.2 - 7.3)
Superior
27 Jan 2023
Fulvestrant or an Aromatase Inhibitor
irkquhighw(lroasnphov) = gadzjjzbwi zcyjgrfeud (scrrjhaccj, 1.9 - 2.1)
Phase 3
ER-positive/HER2-negative Breast Cancer
Second line
ER Positive | HER2 Negative
477
(patients without prior chemotherapy)
kiczocvwyp(gobudmobkq) = kqoajuzwcn nsogxfgkqj (amkwrupchp )
Positive
02 Jun 2022
(patients without prior chemotherapy)
kiczocvwyp(gobudmobkq) = korswdalju nsogxfgkqj (amkwrupchp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free